telisotuzumab adizutecan

Sponsor Abbvie INC. · listed as ABBV

READOUT Phase 3 Confidence: medium Source: clinicaltrials

telisotuzumab adizutecan is a clinical-stage drug asset sponsored by Abbvie INC., listed as ABBV. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Aug 2027 (month precision, medium confidence), tied to trial NCT06614192. The asset is in Phase 3 and currently active not recruiting, studied in Metastatic Colorectal Cancer. It appears across 4 tracked trials in the CSA sample.

Next catalyst

Event typeREADOUT

Expected date2027-08-31

As disclosedAug 2027

Date precisionmonth

Confidencemedium

Verify at source →

Trial & sponsor

Trial (NCT)NCT06614192

PhasePHASE3

StatusACTIVE_NOT_RECRUITING

Lead sponsorAbbVie

Listed asABBV

Condition(s)Metastatic Colorectal Cancer

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.

Get the full dataset — $499 → More ABBV catalysts